Adverse Effects Associated with SBRT in Patients With HCC

Opinion
Video

The panel discusses adverse effects associated with stereotactic body radiation therapy, and the Oncology Brothers provide a recap of the entire discussion.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Related Content
The addition of dendritic cells to TACE in patients with intermediate-stage HCC did not significantly increase the incidence or severity of AEs.

Dendritic Cell Vaccine Shows Preliminary Activity in Advanced HCC

Roman Fabbricatore
September 10th 2025
Article
Govindarajan Narayanan, MD, speaks to the potential time-saving advantages of using the Epione robot for microwave ablation, cryoablation, and other surgical strategies in patients with liver cancer and other tumors.

Adapting to a Robotic Workstation for Image-Guided Liver Cancer Surgery

Govindarajan Narayanan, MD
September 10th 2025
Podcast
Data from the TALENTACE trial support TACE plus atezolizumab/bevacizumab as an effective option in those with unresectable hepatocellular carcinoma.

PFS Improves With TACE-Based Regimen in Unresectable Liver Cancer

Kristi Rosa
September 10th 2025
Article
HAIC with oxaliplatin and raltitrexed produced a higher response rate vs other systemic therapy agents in patients with advanced hepatocellular carcinoma.

HAIC Regimen Yields Long-Term Survival in Unresectable HCC

Russ Conroy
September 10th 2025
Article
SIR-Sphere Y-90 resin microspheres are the only approved radioembolization treatments in the US for both HCC and mCRC.

FDA Approves SIR-Sphere Y-90 in HCC

Ariana Pelosci
September 10th 2025
Article
Survival benefits were observed across most post-hoc subgroups treated with anlotinib plus penpulimab, particularly among those with high-risk disease features.

Anlotinib/Penpulimab Enhances Survival vs Sorafenib in Unresectable HCC

Roman Fabbricatore
September 10th 2025
Article